Tate & Lyle plc (TATE) Fair Value & Analysis
Consumer Defensive · GB · Market cap 2.2B GBX
Fair value as of: Jun 24, 2026
From 24 valuation models · updated 6 days ago
Fair value updated Jun 24, 2026 — revised from £2.68 to £3.10 (+15.7%) since Jun 23, 2026. Share price +9.7% over the past month.
Price vs Fair Value (12 months)
12‑month range £3.29 – £5.68 · fair‑value band £2.44 – £4.90 · the £5.54 price screens above the £3.10 fair value. As of Jun 24, 2026.
✦ Find undervalued quality stocks — 35,000+ analysed Find stocks →Analysis
Tate & Lyle plc (TATE) currently trades at £5.54, while our model-based Fair Value estimate is £3.10 — implying the stock looks roughly 44.0% overvalued today. We read business quality at 97/100 (high quality), in the Consumer Defensive sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Tate & Lyle plc generated revenue of £2.0B at a net margin of 4.8%. Revenue grew 32.1% year over year. It earns a return on equity of 6.2%. Net debt stands at £950M. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Tate & Lyle plc, together with its subsidiaries, engages in the provision of ingredients and solutions to the food, beverages, and other industries in North America, Asia, Middle East, Africa, Latin America, and Europe. Its portfolio includes sweeteners, fibres, stabilisers and functional systems, hydrocolloids, and starches, proteins, and functional flours. The company's products are used in beverages, dairy, soups, sauces and dressings, bakery and snacks, confectionery, household, clinical nutrition, industrial, meat and seafood, and personal care applications. The company has a strategic collaboration with BioHarvest Sciences Inc. The company was incorporated in 1903 and is headquartered in London, the United Kingdom.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Tate & Lyle plc reported revenue of £2.0B in FY2026 versus £1.4B in FY2022, a compound +9.9%/yr. Reported net income was £97.0M in FY2026, compounding −19.9%/yr from FY2022.
Open the full interactive analysis →
Similar stocks
6 more Packaged Foods stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Nestlé S.A NSRGF | $98.16 | $70.25 | -28% |
| Foshan Haitian Flavouring and Food Company 603288 | ¥33.04 | ¥25.65 | -22% |
| Nestlé India Limited NESTLEIND | ₹1,438 | ₹362.37 | -75% |
| Grupo Bimbo, S.A. BIMBOA | 57.10 MXN | 72.19 MXN | +26% |
| Uni-President Enterprises Corp 1216 | 75.10 TWD | 72.54 TWD | -3% |
| Britannia Industries Limited BRITANNIA | ₹5,218 | ₹3,567 | -32% |
Explore undervalued stocks
More undervalued Consumer Defensive stocks →
Frequently asked questions
Is Tate & Lyle plc (TATE) undervalued?
What is the fair value of TATE?
What is the quality score of TATE?
What is the revenue of Tate & Lyle plc (TATE)?
What is the net profit margin of TATE?
Does Tate & Lyle plc pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.